Transaction Information
Capital Raise
SEK 121.9 million
February 2024
Sole Global Coordinator
About Kancera AB (publ)
Kancera is developing a new class of small molecule drugs targeting the fractalkine axis. Kancera’s main focus is to develop its candidate drugs for treatment of severe inflammatory diseases and cancer that currently lack effective treatments. The stock is traded on the Nasdaq First North Premier Growth Market.
The case
SEK 17.5m Capital Raise
Q2 2025
SEK 30m Capital Raise
Q2 2025
SEK 50m Capital Raise
Q2 2025
SEK 61,5m Capital Raise
Q2 2025
SEK 59,5m Capital Raise
Q2 2025
SEK 30m Capital Raise
Q2 2025
SEK 115m Capital Raise
Q2 2025
SEK 25m Capital Raise
Q1 2025
SEK 26.6m Capital Raise
Q4 2024
SEK 280m Capital Raise
Q4 2024
SEK 36.8m Capital Raise
Q4 2024
SEK 60m Capital Raise
Q4 2024